Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to ¹³¹ I-MIBG in patients with relapsed/refractory neuroblastoma.

ABSTRACT:

Background

Prior studies suggest that norepinephrine transporter (NET) and vesicular monoamine transporter 2 (VMAT2) mediate meta-iodobenzylguanidine (MIBG) uptake and retention in neuroblastoma tumors. We evaluated the relationship between NET and VMAT2 tumor expression and clinical response to ¹³¹ I-MIBG therapy in patients with neuroblastoma.

Methods

Immunohistochemistry (IHC) was used to evaluate NET and VMAT2 protein expression levels on archival tumor samples (obtained at diagnosis or relapse) from patients with relapsed or refractory neuroblastoma treated with ¹³¹ I-MIBG. A composite protein expression H-score was determined by multiplying a semi-quantitative intensity value (0-3+) by the percentage of tumor cells expressing the protein.

Resul

SUBMITTER: Batra V 

PROVIDER: S-EPMC10842219 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature